Environment &
Food & Beverage
Cosmetics
Life Sciences
Metal & Mining Industry
Petrochemical & General Chemistry
Automotive Related & Interior Materials
InertSearch (Application Library)
Index
Application
LC
Document No. Index
LB502 - 600 of Application List
| No. | Description | Column |
|---|---|---|
| LB502 | Analysis of Warfarin Potassium (Under the Condition of the Japanese Pharmacopoeia 17th edition) | InertSustain Cyano |
| LB503 | Analysis of Warfarin Potassium (Under the Condition of the Japanese Pharmacopoeia 17th edition, (3) Related subatances) | InertSustain Cyano |
| LB504 | Analysis of Fipronil | InertSustainSwift C18 |
| LB505 | Analysis of Maltooligosaccharides | InertSphere Sugar-1 |
| LB506 | Analysis of Neonicotinoids | InertSustain C18 |
| LB507 | Analysis of Fatty acids by LC/MS/MS | InertSustain AQ-C18 |
| LB508 | Analysis of Sitagliptin (Under the Condition of the draft for the Japanese Pharmacopoeia, Sitagliptin Phosphate Hydrate) | InertSustain Cyano |
| LB509 | Analysis of Angiotensin | InertSustainBio C18 |
| LB510 | Analysis of Estradiol and Progesterone (Under the Condition of the draft for the Japanese Standards of Quasi-drug Ingredients, Placental Extract) | InertSustainSwift C18 |
| LB511 | Analysis of Parabens, Estradiol and Progesterone | InertSustainSwift C18 |
| LB512 | Analysis of Pioglitazone hydrochloride （Under the Condition of the draft for USP） | InertSustain C18 |
| LB513 | Analysis of Peptide hormones | InertSustainBio C18 |
| LB514 | Analysis of Oligonucleotides | InertSustainSwift C18 |
| LB515 | Analysis of Caffeine (Under the Condition of the Japanese Standards of Quasi-drug Ingredients, Coffee Extract) | InertSustain C18 |
| LB516 | (Under the Condition of the Japanese Standards of Quasi-drug Ingredients, Coffee Extract) | InertSustain C18 |
| LB517 | Analysis of Glycyrrhizic acid (Under the Condition of the Japanese Standards of Quasi-drug Ingredients, Glycyrrhiza Extracted Powder) | InertSustain C18 |
| LB518 | Analysis of Glycyrrhetinic acid (Under the Condition of the Japanese Standards of Quasi-drug Ingredients, Monoammonium α-Glycyrrhizinate) | InertSustain C18 |
| LB519 | Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) | InertSustainSwift C18 |
| LB520 | Analysis of Valsartan and Hydrochlorothiazide(Under the Condition of the draft for the Japanese Pharmacopoeia, Valsartan and Hydrochlorothiazide Tablets) | InertSustain C18 |
| LB521 | Analysis of Folic acid | InertSustain C18 |
| LB522 | Analysis of Glutathione and its related compounds | InertSustain AQ-C18 |
| LB523 | Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) | Inertsil C8-3 |
| LB524 | Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the Japanese Pharmacopoeia supplement II, Telmisartan and Hydrochlorothiazide Tablets) | Inertsil C8-3 |
| LB525 | Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of the draft for the Japanese Pharmacopoeia, Telmisartan and Hydrochlorothiazide Tablets) | Inertsil C8-3 |
| LB526 | Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) | Inertsil ODS-4 |
| LB527 | Analysis of Dexamathasone Sodium Phosphate (Under the Condition of the draft for the Japanese Pharmacopoeia, Dexamathasone Sodium Phosphate) | Inertsil ODS-4 |
| LB528 | Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc) | InertSustain C18 |
| LB529 | Analysis of Carnosine (Under the Condition of the draft for the Japanese Pharmacopoeia, Poraprezinc Granules) | InertSustain C18 |
| LB530 | Analysis of Oligosaccharides derivatized with 2-Aminobenzamide (2-AB) | InertSustain Amide |
| LB531 | Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets A) | InertSustain C18 |
| LB532 | Analysis of Sodium Valproate (Under the Condition of the draft for the Japanese Pharmacopoeia, Sodium Valproate Extended-release Tablets B) | InertSustain C18 |
| LB533 | Analysis of Dexamathasone Sodium Phosphate (Under the Condition of USP41-NF36, Dexamathasone Sodium Phosphate) | Inertsil ODS-3 |
| LB534 | Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) | InertSustain C8 |
| LB535 | Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) | InertSustainSwift C8 |
| LB536 | Analysis of Telmisartan and Hydrochlorothiazide (Under the Condition of USP41-NF36, Telmisartan and Hydrochlorothiazide Tablets) | InertSustain C18 |
| LB537 | Analysis of Suger Alcohol | InertSustain Amide |
| LB538 | Analysis of Organic acid | SYPRON AX-2 |
| LB539 | Analysis of 6 kinds of Aldehydes Specified in Japanese Offensive Odor Control Law (Detected by Pre-Column Method with DNPH) | InertSustain PFP |
| LB540 | Analysis of 6 kinds of Aldehydes Specified in Japanese Offensive Odor Control Law (Detected by Pre-Column Method with DNPH) | InertSustain PFP |
| LB541 | Analysis of 6 kinds of Aldehydes Specified in Japanese Offensive Odor Control Law (Detected by Pre-Column Method with DNPH) | Inertsil C8-4 |
| LB542 | Analysis of D-Mannitol (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), D-Mannitol and Corn starch compound) | InertSphere Sugar-2 |
| LB543 | Analysis of Xylooligosaccharides | InertSphere Sugar-1 |
| LB544 | Analysis of Catecholamines | InertSustain AQ-C18 |
| LB545 | Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) | InertSustainSwift C18 |
| LB546 | Analysis of Cinacalcet Hydrochloride (Under the Condition of draft for USP) | InertSustainSwift C18 |
| LB547 | Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) | InertSustain C18 |
| LB548 | Analysis of Sitagliptin (Under the Condition of draft for USP, Sitagliptin and Metformin Hydrochloride Tablets) | InertSustain C18 |
| LB549 | Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe) | InertSustain PFP |
| LB550 | Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) | InertSustainSwift C18 |
| LB551 | Analysis of Ezetimibe (Under the Condition of USP41-NF36, Ezetimibe Tablets) | InertSustainSwift C18 |
| LB552 | Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine) | InertSustain C18 |
| LB553 | Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine Tablets) | InertSustain C18 |
| LB554 | Analysis of Mirtazapine (Under the Condition of USP41-NF36, Mirtazapine Orally Disintegrating Tablets) | InertSustainSwift C18 |
| LB555 | Analysis of Mirtazapine (Under the Condition of draft for USP, Mirtazapine Compounded Oral Suspension, Veterinary) | Inertsil ODS-3 |
| LB556 | Analysis of Mirtazapine | InertSustain C18 |
| LB557 | Analysis of 16 Aldehyde (Detected by Pre-Column Method with DNPH) | InertSustain PFP |
| LB558 | Analysis of 16 Aldehyde (Detected by Pre-Column Method with DNPH) | InertSustain PFP |
| LB559 | Analysis of Artificial sweeteners | InertSustain AQ-C18 |
| LB560 | Analysis of Advantame (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives)) | InertSustain AQ-C18 |
| LB561 | Analysis of Neotame (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives)) | InertSustain AQ-C18 |
| LB562 | Analysis of Steviol (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), Purified Stevia Extract (4) Steviol) | Inertsil ODS-HL |
| LB563 | Analysis of Steviol (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), Purified Stevia Extract (4) Steviol) | InertSustain AQ-C18 |
| LB564 | Analysis of Steviol glycosides (Under the Condition of the JPE (Japanese Pharmaceutical Excipients), Purified Stevia Extract Assay) | Inertsil NH2 |
| LB565 | Analysis of Steviol glycosides (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives), Stevia Extract) | Inertsil ODS-HL |
| LB566 | Analysis of Steviol glycosides (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives), Stevia Extract) | InertSustain AQ-C18 |
| LB567 | Analysis of Steviol glycosides (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives), Steviol Glycosides) | Inertsil ODS-HL |
| LB568 | Analysis of Steviol glycosides (Under the Condition of the JSFA-IX (Japanese Standards of Food Additives), Steviol Glycosides) | InertSustain AQ-C18 |
| LB569 | Analysis of Steviol glycosides (Under the Condition of the JSFA-VIII (Japanese Standards of Food Additives), Stevia Extract) | InertSustain NH2 |
| LB570 | Analysis of Steviol glycosides (Under the Condition of the JSFA-VIII (Japanese Standards of Food Additives), Stevia Extract) | Inertsil NH2 |
| LB571 | Analysis of Nicotinamide Adenine Dinucleotide (NADH, NAD+) | InertSustain PFP |
| LB572 | Analysis of Nucleosides | InertSustain PFP |
| LB573 | Analysis of Dipeptides | InertSustain PFP |
| LB574 | Analysis of Catecholamines | InertSustain PFP |
| LB575 | Analysis of Tryptophan and its related compounds | InertSustain PFP |
| LB576 | Analysis of Uric Acid and its related compounds | InertSustain PFP |
| LB577 | Analysis of Glutathione | InertSustain PFP |
| LB578 | Analysis of Cysteine and its related compounds | InertSustain PFP |
| LB579 | Analysis of Lysine, Methionine, and Carnitine | InertSustain PFP |
| LB580 | Analysis of Urea, Ornithine, and Arginine | InertSustain PFP |
| LB581 | Analysis of Choline and Acetylcholine | InertSustain PFP |
| LB582 | Analysis of Amino Acids | InertSustain PFP |
| LB584 | Analysis of Melamine and its related compounds | InertSustain PFP |
| LB585 | Analysis of Unsaturated fatty acids | InertSustain PFP |
| LB586 | Analysis of Sterols | InertSustain PFP |
| LB587 | Analysis of Eugenol | InertSustain PFP |
| LB588 | Analysis of Antidepressants | InertSustain PFP |
| LB589 | Analysis of β-blockers | InertSustain PFP |
| LB590 | Analysis of Antihistamines | InertSustain PFP |
| LB591 | Analysis of Antihistamines | InertSustain PFP |
| LB592 | Analysis of Antihistamines | InertSustain PFP |
| LB593 | Analysis of Steroids | InertSustain PFP |
| LB594 | Analysis of Estrogen | InertSustain PFP |
| LB595 | Analysis of Acetyldeoxynivalenol (AcDON) | InertSustain PFP |
| LB596 | Analysis of Amino Acids with HILIC mode separtaion | InertSustain Amide |
| LB597 | Analysis of 11 Drugs | MonoSelect C18 for HTS |
| LB598 | Analysis of Acephate and Methamidophos | MonoSelect C18 for HTS |
| LB599 | Analysis of Hydroquinone, Resorcinol, and Catechol | MonoSelect C18 for HTS |
| LB600 | Analysis of Fumonisin B1 | MonoSelect C18 for HTS |